title: Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?
authors.affiliation: Economic Evaluation Service, Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA.
authors.forename: Bijan J
authors.initials: BJ
authors.lastname: Borah
authors.affiliation: Department of Cardiovascular Diseases, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
authors.forename: Naveen
authors.initials: N
authors.lastname: Pereira
authors.affiliation: Peter Munk Cardiac Centre & Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Canada. michael.farkouh@uhn.ca.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Farkouh
mesh_terms: D054058:Acute Coronary Syndrome; D003362:Cost-Benefit Analysis; D006801:Humans; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors
chemical_list: D010975:Platelet Aggregation Inhibitors